Stockscreener 앱 받기
1.32
0.76%
0.01
시간 외 거래:
1.32
전일 마감가:
$1.31
열려 있는:
$1.3
하루 거래량:
3,996
Relative Volume:
0.09
시가총액:
$36.04M
수익:
$9.06M
순이익/손실:
$-50.39M
주가수익비율:
-0.6875
EPS:
-1.92
순현금흐름:
$5.89M
1주 성능:
+1.15%
1개월 성능:
+0.00%
6개월 성능:
+24.53%
1년 성능:
-26.67%
1일 변동 폭
$1.30
$1.34
1주일 범위
$1.29
$1.38
52주 변동 폭
$0.8502
$2.39
Lava Therapeutics Nv Stock (LVTX) Company Profile
명칭
Lava Therapeutics Nv
전화
31 6 3000 3035
주소
YALELAAN 62, UTRECHT
LVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.32 | 36.04M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | 개시 | H.C. Wainwright | Buy |
| 2021-04-19 | 개시 | JP Morgan | Overweight |
| 2021-04-19 | 개시 | Jefferies | Buy |
| 2021-04-19 | 개시 | SVB Leerink | Outperform |
모두보기
Lava Therapeutics Nv 주식(LVTX)의 최신 뉴스
LAVA Therapeutics Shareholders Approve Key Proposals in Meeting - TipRanks
LAVA Therapeutics NV reports results for the quarter ended March 31Earnings Summary - TradingView
Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation - Yahoo Finance
LAVA Therapeutics (LVTX) Receives Reiterated Market Perform Rati - GuruFocus
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update - GlobeNewswire
LAVA (LVTX) Pursues Strategic Moves Amid Workforce Restructuring - GuruFocus
LAVA Therapeutics Slashes 30% Workforce, Closes Netherlands Operations Amid Strategic Review - Stock Titan
LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq
Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire
LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan
Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India
LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World
Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa
Leerink cuts Lava Therapeutics stock target to $1 - Investing.com
JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia
JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com
Lava Therapeutics Reports 2024 Financial Results - TipRanks
LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia
LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz
LAVA Therapeutics NV SEC 10-K Report - TradingView
LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener
LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments - Stock Titan
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq
LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks
LAVA Announces Evaluation of Strategic Options - GlobeNewswire
Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan
LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia
LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
Lava Therapeutics Nv (LVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.68%
0.50%
자본화:
|
볼륨(24시간):